Skip to main content
Top
Published in: European Spine Journal 12/2018

01-12-2018 | Original Article

Total spondylectomy for Enneking stage III giant cell tumor of the mobile spine

Authors: Noriaki Yokogawa, Hideki Murakami, Satoru Demura, Satoshi Kato, Katsuhito Yoshioka, Takaki Shimizu, Norihiro Oku, Ryo Kitagawa, Hiroyuki Tsuchiya

Published in: European Spine Journal | Issue 12/2018

Login to get access

Abstract

Purpose

We reported the surgical outcomes of total en bloc spondylectomy (TES) with intralesional T-saw transpedicular osteotomy in patients with Enneking stage III spinal giant cell tumors (GCTs).

Methods

The medical records and imaging and pathological studies of 25 consecutive patients with Enneking stage III spinal GCTs undergoing surgery at our institution who were followed for at least 2 years were retrospectively reviewed.

Results

Eight men and 17 women (mean age: 34.2 years, range 16–51 years, at the time of surgery) were included. Six patients underwent previous tumor excision at another hospital, and one patient had a history of denosumab treatment. The GCTs were at the cervical, thoracic, and lumbar levels in three, nine, and 13 patients, respectively. TES was performed in 13 patients; 12 required intralesional pediculotomy. The remaining patients underwent total piecemeal spondylectomy with further intralesional tumor resection. During a mean follow-up of 99.2 months (range 24–216), two patients who underwent total piecemeal spondylectomy had local tumor recurrence, but no patients who underwent TES with intralesional pediculotomy had recurrence. The 2- and 10-year recurrence-free survival rates of patients treated with total piecemeal spondylectomy were 91.7% and 78.6%, respectively, while those of patients treated with TES were both 100%.

Conclusions

TES with intralesional pediculotomy had a good surgical outcome even in patients with Enneking stage III spinal GCT, suggesting that minimal intralesional procedures could radically cure spinal GCTs.

Graphical abstract

These slides can be retrieved under Electronic Supplementary Material.
Appendix
Available only for authorised users
Literature
1.
go back to reference Boriani S, Bandiera S, Casadei R, Boriani L, Donthineni R, Gasbarrini A, Pignotti E, Biagini R, Schwab JH (2012) Giant cell tumor of the mobile spine: a review of 49 cases. Spine (Phila Pa 1976) 371:E37–E45CrossRef Boriani S, Bandiera S, Casadei R, Boriani L, Donthineni R, Gasbarrini A, Pignotti E, Biagini R, Schwab JH (2012) Giant cell tumor of the mobile spine: a review of 49 cases. Spine (Phila Pa 1976) 371:E37–E45CrossRef
2.
go back to reference Campanacci M, Baldini N, Boriani S, Sudanese A (1987) Giant-cell tumor of bone. J Bone Joint Surg Am 69:106–114CrossRef Campanacci M, Baldini N, Boriani S, Sudanese A (1987) Giant-cell tumor of bone. J Bone Joint Surg Am 69:106–114CrossRef
3.
go back to reference Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Gosheger G (2008) Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134:969–978CrossRef Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Gosheger G (2008) Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134:969–978CrossRef
4.
go back to reference Luksanapruksa P, Buchowski JM, Singhatanadgige W, Rose PC, Bumpass DB (2016) Management of spinal giant cell tumors. Spine J 16:259–269CrossRef Luksanapruksa P, Buchowski JM, Singhatanadgige W, Rose PC, Bumpass DB (2016) Management of spinal giant cell tumors. Spine J 16:259–269CrossRef
5.
go back to reference Elder BD, Sankey EW, Goodwin CR, Kosztowski TA, Lo SF, Bydon A, Wolinsky JP, Gokaslan ZL, Witham TF, Sciubba DM (2016) Surgical outcomes in patients with high spinal instability neoplasm score secondary to spinal giant cell tumors. Glob Spine J 6:21–28CrossRef Elder BD, Sankey EW, Goodwin CR, Kosztowski TA, Lo SF, Bydon A, Wolinsky JP, Gokaslan ZL, Witham TF, Sciubba DM (2016) Surgical outcomes in patients with high spinal instability neoplasm score secondary to spinal giant cell tumors. Glob Spine J 6:21–28CrossRef
6.
go back to reference Tomita K, Kawahara N, Baba H, Tsuchiya H, Fujita T, Toribatake Y (1997) Total en bloc spondylectomy: a new surgical technique for primary malignant vertebral tumors. Spine (Phila Pa 1976) 22:324–333CrossRef Tomita K, Kawahara N, Baba H, Tsuchiya H, Fujita T, Toribatake Y (1997) Total en bloc spondylectomy: a new surgical technique for primary malignant vertebral tumors. Spine (Phila Pa 1976) 22:324–333CrossRef
7.
go back to reference Enneking WF (1986) A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 204:9–24 Enneking WF (1986) A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 204:9–24
8.
go back to reference Hart RA, Boriani S, Biagini R, Currier B, Weinstein JN (1997) A system for surgical staging and management of spine tumors. A clinical outcome study of giant cell tumors of the spine. Spine (Phila Pa 1976) 22:1773–1782CrossRef Hart RA, Boriani S, Biagini R, Currier B, Weinstein JN (1997) A system for surgical staging and management of spine tumors. A clinical outcome study of giant cell tumors of the spine. Spine (Phila Pa 1976) 22:1773–1782CrossRef
9.
go back to reference Tomita K, Kawahara N, Baba H, Tsuchiya H, Nagata S, Toribatake Y (1994) Total en bloc spondylectomy for solitary spinal metastases. Int Orthop 18:291–298CrossRef Tomita K, Kawahara N, Baba H, Tsuchiya H, Nagata S, Toribatake Y (1994) Total en bloc spondylectomy for solitary spinal metastases. Int Orthop 18:291–298CrossRef
10.
go back to reference Harrop JS (2009) Aggressive “benign” primary spine neoplasms. Spine (Phila Pa 1976) 34:S39–S47CrossRef Harrop JS (2009) Aggressive “benign” primary spine neoplasms. Spine (Phila Pa 1976) 34:S39–S47CrossRef
11.
go back to reference Xu W, Li X, Huang W, Wang Y, Han S, Chen S, Xu L, Yang X, Liu T, Xiao J (2013) Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center. Ann Surg Oncol 20:804–810CrossRef Xu W, Li X, Huang W, Wang Y, Han S, Chen S, Xu L, Yang X, Liu T, Xiao J (2013) Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center. Ann Surg Oncol 20:804–810CrossRef
12.
go back to reference Junming M, Cheng Y, Dong C, Jianru X, Xinghai Y, Quan H, Wei Z, Mesong Y, Dapeng F, Wen Y, Bin N, Lianshun J, Huimin L (2008) Giant cell tumor of the cervical spine: a series of 22 cases and outcomes. Spine (Phila Pa 1976) 33:280–288CrossRef Junming M, Cheng Y, Dong C, Jianru X, Xinghai Y, Quan H, Wei Z, Mesong Y, Dapeng F, Wen Y, Bin N, Lianshun J, Huimin L (2008) Giant cell tumor of the cervical spine: a series of 22 cases and outcomes. Spine (Phila Pa 1976) 33:280–288CrossRef
13.
go back to reference Luksanapruksa P, Buchowski JM, Singhatanadgige W, Bumpass DB (2016) Systematic review and meta-analysis of en bloc vertebrectomy compared with intralesional resection for giant cell tumors of the mobile spine. Glob Spine J 6:798–803CrossRef Luksanapruksa P, Buchowski JM, Singhatanadgige W, Bumpass DB (2016) Systematic review and meta-analysis of en bloc vertebrectomy compared with intralesional resection for giant cell tumors of the mobile spine. Glob Spine J 6:798–803CrossRef
14.
go back to reference Lewin J, Thomas D (2013) Denosumab: a new treatment option for giant cell tumor of bone. Drugs Today (Barc) 49:693–700CrossRef Lewin J, Thomas D (2013) Denosumab: a new treatment option for giant cell tumor of bone. Drugs Today (Barc) 49:693–700CrossRef
15.
go back to reference Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S (2010) Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 11:275–280CrossRef Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S (2010) Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 11:275–280CrossRef
16.
go back to reference Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14:901–908CrossRef Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14:901–908CrossRef
17.
go back to reference Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA (2015) Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 22:2860–2868CrossRef Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA (2015) Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 22:2860–2868CrossRef
18.
go back to reference Lin P, Lin N, Teng W, Wang SD, Pan WB, Huang X, Yan XB, Liu M, Li HY, Li BH, Sun LL, Wang Z, Zhou XZ, Ye ZM (2018) Recurrence of giant cell tumor of the spine after resection: a report of 10 cases. Orthop Surg 10:107–114CrossRef Lin P, Lin N, Teng W, Wang SD, Pan WB, Huang X, Yan XB, Liu M, Li HY, Li BH, Sun LL, Wang Z, Zhou XZ, Ye ZM (2018) Recurrence of giant cell tumor of the spine after resection: a report of 10 cases. Orthop Surg 10:107–114CrossRef
19.
go back to reference Kumar R, Meis JM, Amini B, McEnery KW, Madewell JE, Rhines LD, Benjamin RS (2017) Giant cell tumor of cervical spine presenting as acute asphyxia: successful surgical resection after down-staging with denosumab. Spine (Phila Pa 1976) 42:e629–632CrossRef Kumar R, Meis JM, Amini B, McEnery KW, Madewell JE, Rhines LD, Benjamin RS (2017) Giant cell tumor of cervical spine presenting as acute asphyxia: successful surgical resection after down-staging with denosumab. Spine (Phila Pa 1976) 42:e629–632CrossRef
20.
go back to reference Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P (2016) Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res 6:15CrossRef Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P (2016) Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res 6:15CrossRef
21.
go back to reference Broehm CJ, Garbrecht EL, Wood J, Bocklage T (2015) Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep Med 2015:767198CrossRef Broehm CJ, Garbrecht EL, Wood J, Bocklage T (2015) Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep Med 2015:767198CrossRef
22.
go back to reference Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL (2015) A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res 473:3050–3055CrossRef Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL (2015) A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res 473:3050–3055CrossRef
23.
go back to reference Mak IW, Evaniew N, Popovic S, Tozer R, Ghert M (2014) A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 96:e127CrossRef Mak IW, Evaniew N, Popovic S, Tozer R, Ghert M (2014) A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 96:e127CrossRef
24.
go back to reference Yonezawa N, Murakami H, Kato S, Takeuchi A, Tsuchiya H (2017) Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy. Eur Spine J 26:236–242CrossRef Yonezawa N, Murakami H, Kato S, Takeuchi A, Tsuchiya H (2017) Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy. Eur Spine J 26:236–242CrossRef
25.
go back to reference Matcuk GR, Patel DB, Schein AJ, White EA, Menendez LR (2015) Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skelet Radiol 44:1027–1031CrossRef Matcuk GR, Patel DB, Schein AJ, White EA, Menendez LR (2015) Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skelet Radiol 44:1027–1031CrossRef
26.
go back to reference Patil S, Shah KC, Bhojraj SY, Nene AM (2016) Recurrent spinal giant cell tumors: a study of risk factors and recurrence patterns. Asian Spine J 10:129–135CrossRef Patil S, Shah KC, Bhojraj SY, Nene AM (2016) Recurrent spinal giant cell tumors: a study of risk factors and recurrence patterns. Asian Spine J 10:129–135CrossRef
Metadata
Title
Total spondylectomy for Enneking stage III giant cell tumor of the mobile spine
Authors
Noriaki Yokogawa
Hideki Murakami
Satoru Demura
Satoshi Kato
Katsuhito Yoshioka
Takaki Shimizu
Norihiro Oku
Ryo Kitagawa
Hiroyuki Tsuchiya
Publication date
01-12-2018
Publisher
Springer Berlin Heidelberg
Published in
European Spine Journal / Issue 12/2018
Print ISSN: 0940-6719
Electronic ISSN: 1432-0932
DOI
https://doi.org/10.1007/s00586-018-5761-3

Other articles of this Issue 12/2018

European Spine Journal 12/2018 Go to the issue

Announcements

Announcements